• 1
    Moher D, Schulz KF, Altman DG. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 11911194.
  • 2
    Schold JD, Kaplan B. Design and analysis of clinical trials in transplantation: Principles and pitfalls. Am J Transplant 2008; 8: 17791785.
  • 3
    Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995; 345: 16161619.
  • 4
    Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q 2004; 82: 661687.
  • 5
    Ioannidis JP, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: A proposed evaluation algorithm. Am J Epidemiol 1998; 148: 11171126.
  • 6
    Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification. JAMA 2007; 298: 12091212.
  • 7
    Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355: 10641069.
  • 8
    Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992; 116: 7884.
  • 9
    Jassal SV, Schaubel DE, Fenton SS. Baseline comorbidity in kidney transplant recipients: A comparison of comorbidity indices. Am J Kidney Dis 2005; 46: 136142.
  • 10
    Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol 2006; 6: 18.
  • 11
    Kent DM, Hayward RA, Griffith JL et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med 2002; 113: 104111.
  • 12
    Kent DM, Jafar TH, Hayward RA et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007; 18: 19591965.
  • 13
    Vijan S, Kent DM, Hayward RA. Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus? Diabetologia 2000; 43: 125130.
  • 14
    U.S.Food and Drug Administration. Xigris product information. Available from: 2009
  • 15
    Tantravahi J, Womer KL, Kaplan B. Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med 2007; 58: 369385.
  • 16
    Meier-Kriesche HU, Ojo AO, Hanson JA et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70: 10981100.
  • 17
    A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61: 10291037.
  • 18
    Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998; 65: 14501454.
  • 19
    Hazzan M, Buob D, Labalette M et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 2006; 82: 657662.
  • 20
    Ekberg H. Graft survival benefit to be expected of new immunosuppressive regimens. Transplant Rev 2003; 17: 187193.
  • 21
    Aydingoz SE, Takemoto SK, Pinsky BW et al. The impact of human leukocyte antigen matching on transplant complications and immunosuppression dosage. Hum Immunol 2007; 68: 491499.
  • 22
    Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD. Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation 1991; 51: 338342.
  • 23
    Sanfilippo F, Vaughn WK, LeFor WM, Spees EK. Multivariate analysis of risk factors in cadaver donor kidney transplantation. Transplantation 1986; 42: 2834.
  • 24
    Thibaudin D, Alamartine E, De Filippis JP, Diab N, Laurent B, Berthoux F. Advantage of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998; 13: 711715.
  • 25
    Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580590.
  • 26
    Halloran PF. Immunosuppressive drugs for kidney transplantation. [erratum appears in N Engl J Med 2005;352:1056]. [Review][124 refs]. N Engl J Med 2004; 351: 27152729.
  • 27
    Kasiske BL, Israni AK, Snyder JJ, Skeans MA, Weinhandl ED, Peng Y. Cardiac events post kidney transplantation: Interim results from the patient outcomes in renal transplantation (PORT) international transplant study. Am J Transplant 2008; 8[s2]: 177336. Ref Type: Abstract
  • 28
    Webster AC, Playford EG, Higgins G, Chapman JR, Craig J. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2004;CD003897.
  • 29
    Schmid CH, Stark PC, Berlin JA, Landais P, Lau J. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. J Clin Epidemiol 2004; 57: 683697.
  • 30
    Hanaway M, Woodle SE, Mulgaonkar S et al. Twelve-month results of a multicenter, randomized trial comparing three induction agents (Alemtuzumab, Thymoglobulin and Basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation. Am J Transplant 2008; 8: 177336.